A small molecule antagonist of CXCR1/2 (SCH563705) in combination with lapatinib (HER2/neu and epidermal growth factor receptor inhibitor) was more effective in reducing mammosphere formation efficiency in HER2+ cancers when compared to single agents [65]. The gene discussed is ERBB2; the disease is cancer.